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Accepted 17 January 2012; Published online 31 May 2012AbstractObjective: The pros and cons of composite end points in prognostic research are discussed, and an adaptation method, designed to
accurately adjust absolute risks for a composite end point to risks for the individual component outcomes, is presented.
Study Design and Setting: An example prediction model for recurrent cardiovascular events (composite end point) was used to eval-
uate the performance regarding the individual component outcomes (cardiovascular death, myocardial infarction, and stroke) before and
after the adaptation method.
Results: Discrimination for the individual component outcomes (concordance index for myocardial infarction, 0.68; concordance index
for stroke, 0.70) was very similar to discrimination for the original composite end point (concordance index, 0.70). For cardiovascular
death, it even increased substantially (concordance index, 0.78). After adaptation, calibration plots for the component outcomes also im-
proved, with visible convergence of the predicted risks and the observed incidences.
Conclusion: In sum, these findings show that the adaptationmethod is useful whenvalidating or applying a composite end point prediction
model to the individual component outcomes. Following from this, recommendations concerning reporting of composite end points in future
research are also included.Without the need for extra data, composite end point prediction models can easily be directly expanded to allow for
the estimation of risk for each individual component outcome, improving the interpretability for clinicians and patients.
 2012 Elsevier Inc.
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Prediction research commonly involves individual esti-
mation of absolute risks for future outcomes based on ob-
served characteristics [1]. This is clinically useful, as it
helps to inform patients about their risk for future illnesses,
can motivate them to change unhealthy lifestyles, can in-
creasemedical compliance, and can guide physicians in their
decisions for further treatment [1,2]. Prediction models re-
ported indespecially cardiovasculardliterature frequently
provide absolute risks for composite end points rather than
for discrete individual end points [3e6]. This may be done
to increase study power or to enable risk stratification for
a particular, usually related, group of events, such as cardio-
vascular disease. Well-known examples are the Framingham* Corresponding author. Tel.: þ31-8-8755-5555; fax: þ31-8-8756-
8099.
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Open access under the Elsevier OA license.Risk Score (predicting a composite of angina pectoris, rec-
ognized and unrecognized myocardial infarction, coronary
insufficiency, and death from coronary heart disease) [7]
and the recently developed Reynolds risk score (predicting
myocardial infarction, ischemic stroke, coronary revascular-
ization, and cardiovascular death) [3].
Drawbacks of composite end points were previously de-
scribed in other research settings, especially randomized tri-
als [8e11]. Montori et al. [12] reacted to this by presenting
a guideline for the interpretation of composite end points in
clinical trials. They propose subjecting composite end points
to three test questions, corresponding to the major draw-
backs of composite end points in clinical trials: (1) Will
the patients consider the individual components of the
composite-endpoints to be of similar importance? (2) Are
the frequencies of the different individual components sim-
ilar? (3) Are the effects of the intervention similar for each of
the individual components? Answering these questions
would help readers differentiate between clinical trials in
which a simple interpretation of reported composite end
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Key finding:
- The key findings show that our proposed adapta-
tion method is useful when validating or applying
a composite end point (CEP) prediction model to
the individual component outcomes.
Already known:
- CEPs increase study power.
- CEPs are helpful to identify high-risk patients for
a specific group of diseases.
- CEPs are difficult to interpret regarding the indi-
vidual component outcomes, also in prediction
research.
- CEPs lack in relevance to patients.
New aspects for CEPs in prediction research:
- Risks for CEPs in prediction research cannot
directly be ascribed to individual end points.
- Risk for individual component outcomes in predic-
tion research can be accurately estimated with
a simple adaptation method that adjusts the base-
line hazard.
Recommendations for using CEPs in prediction
research:
- Incidence of the CEP and individual component
outcomes should be clearly described.
- Baseline hazard(s) of fitted prediction model
should be presented.
- Performance of prediction model with the CEP as
well as the individual component outcomes should
be evaluated before they can safely be applied.
- Present nomograms/score charts for CEP and indi-
vidual component outcomes.points is appropriate and those in which interpretation is
necessarily more complex.
Although underexposed in previous methodology litera-
ture, composite end points interpretation issues are also rel-
evant to prognostic research. Besides the absolute risks for
a composite end point, the absolute risks for individual
component outcomes may also be pertinent to patients
and physicians. Reasons are that individual component out-
comes require different treatment strategies or may differ
in impact on patient’s lives. Consider the composite end
point used for the Reynolds risk score (described above):
although a major stroke is often more debilitating thancoronary revascularization, the prediction model does not
discriminate between these two individual component
outcomes and tallies them equally. Similarity in the fre-
quencies of component outcomes might also relate to prog-
nostic research. Generally, the frequencies of the individual
component outcomes differ. Consequently, the absolute
risks for composite end points cannot directly be applied
to the individual component outcomes, as it would result
in incorrect conclusions with regard to patient’s risk for
a specific individual component.
The use of composite end points in prognostic research
is investigated in this study. Data from the Second Manifes-
tations of ARTerial disease (SMART) study were used to
illustrate the pitfalls encountered when translating absolute
risks for composite end points to individual component out-
comes. A novel and practical adaptation method by which
absolute risks reported for composite end points can be ad-
justed for the interpretation of the individual component
outcomes is also presented. In addition, we discuss some
suggestions how studies incorporating a prediction model
for composite end points could be reported in a manner that
facilitates their use by other researchers in validation stud-
ies or even in clinical practice.2. Design and setting
The SMART study is an ongoing, prospective dynamic
cohort study among subjects with a symptomatic vascular
disease aimed at establishing the prevalence of concomitant
arterial diseases and risk factors for subsequent cardiovascu-
lar (re)events [13]. Patients, aged 18 to 79 years, who were
newly referred to the University Medical Center Utrecht
with symptomatic manifest vascular disease between March
1996 and February 2007 were included in this study. The
SMART study was approved by the ethics committee. Eligi-
ble patients received written and oral information about the
goals and logistics of the study at their visit to the hospital.
All patients were asked for written informed consent.
A composite end point prediction model for 3- and 5-year re-
current cardiovascular events (composite end point) was de-
rived with Cox proportional hazard analysis in this study to
evaluate the performance regarding its individual compo-
nent outcomes (cardiovascular death, myocardial infarction,
and stroke) (Table 1) before and after applying the adapta-
tion method. Information about the prediction model, in-
cluding its development, is presented in Appendix A on
the journal’s Web site at www.jclinepi.com.2.1. Adaptation method
We first estimated the model performance (see below)
when simply applying the prediction model (as developed
for predicting the absolute risk of experiencing the compos-
ite end point) to the three individual component outcomes,
using the formula above. This was done for 3- and 5-year
incidenceðcomposite end pointÞ
Table 1. Definitions of outcome events predicted by the example
prediction model
Outcome event Definition
Composite end point Cardiovascular death, myocardial
infarction, or stroke
Cardiovascular
death
Sudden death: unexpected cardiac death
occurring within 1 hr after onset
of symptoms or within 24 hr, given
convincing circumstantial evidence
Death from ischemic stroke
Death from intracerebral hemorrhage
(hemorrhage on CT scan)
Death from congestive heart failure
Death from myocardial infarction
Death from rupture of abdominal aortic
aneurysm
Vascular death from other cause, such
as sepsis following stent placement
Myocardial
infarction:
At least two of the following criteria:
Chest pain for more than 20 min, not
disappearing after administration
of nitrates
ST elevation of O1 mm in leads or
a left bundle branch block on ECG
CK elevation of at least times its normal
value and an MB fraction of O5%
of total CK
Stroke Relevant clinical features that caused an
increase in impairment of at least one
grade on the modified Rankin scale,
accompanied by a fresh ischemic
infarction on a repeat brain scan
Abbreviations: CT, computed tomography; ST, the part between an
S golf and a T wave in an electrocardiogram that denotes the repolar-
ization ability of the heart; ECG, electrocardiogram; CK, creatinine
kinase; MB, myocardial band.
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method to correct the absolute risks of the prediction model
for each individual component outcome and reevaluated the
model performance with these adapted risks. The adapta-
tion method we present consists of three consecutive steps:
In the first step, a calibration factor is calculated. To correct
for the fact that a patient may develop multiple outcome
events (e.g., a myocardial infarction followed by a stroke)
and for varying frequencies of component outcomes during
follow-up period, we propose to calculate the calibration
factor by dividing all observed individual component out-
comes during follow-up by the composite end point’s inci-
dence. In the second step, the baseline hazard is adapted;
this is done by multiplying the original baseline hazard
for a given follow-up with the calibration factor. Finally,
the absolute risks for the individual component outcome
event are calculated using the adapted baseline hazard
and the individual risk score, which is obviously not
affected by the adaptation method. The steps of our adapta-
tion approach can be written as follows (example calcula-
tions are presented in the Appendix B on the journal’s
Web site at www.jclinepi.com):incidenceðcomponent outcomeÞ1. calibration factor 52. adjusted baseline hazard 5 calibration factor
 baseline hazardðpredication modelÞ
3. adapted risk
5 ðexp ðadjusted baseline hazardÞÞexpðrisk scoreÞ
Incidence(component end point) is the incidence of an indi-
vidual component outcome, and incidence(composite end point)
is the incidence of the composite end point in the data set at
hand. Baseline hazard(prediction model) is the baseline hazard
of the original prediction model for a specific period (here
0.062 and 0.107 for 3- and 5-year survival from the com-
posite end point, respectively, see above). Adapted risk is
the risk for a specific individual component outcome ex-
pressed as the chance of being event free giving a specific
period of follow-up.2.2. Assessment of model performance
The adaptation method can only safely be applied if the
adapted risks are accurate. This should always be evaluated.
Therefore, we evaluated the performance of the prediction
model for the composite end point as well as for the indi-
vidual component outcomes by estimating the model dis-
crimination and calibration [14]. Discrimination was
assessed using the concordance index [14,15], which can
be interpreted just like the area under the curve from a re-
ceiver operating characteristic curve [16]. Calibration refers
to the agreement between the predicted risks and the ob-
served incidences and was assessed visually using calibra-
tion plots for 3- and 5-year follow-up separately. Data
management and statistical analysis were performed with
statistical software programs R (version 2.6.1; R Founda-
tion for Statistical Computing, Vienna, Austria) (http://
www.R-project.org) and SPSS (version 14.1; SPSS Inc.,
Chicago, IL, USA).3. Results
Data of this study contained 4,499 patients with symp-
tomatic manifest vascular disease. Ninety-two patients were
excluded, as they were lost in follow-up (2.1%). Table 2
presents the distribution of the predictors and the different
outcomes in our data. The composite end point was 535
times identified during follow-up (mean, 1,460 days). A sub-
stantial group of patients experienced more than one event:
cardiovascular death occurred 324 times (mean follow-up,
1,554 days), myocardial infarction was identified 310 times
(mean follow-up, 1,513 days), and stroke was identified 136
times (mean follow-up, 1,526 days). This means that only
Table 2. Distribution of the predictors and the different outcomes for the study population, 1996e2007
Determinants and outcomes SMART cohort, N[ 4,407 Missing data, N (%)
Predictors
Age, yr, mean (minemax) 59 (19e82) 0
Body mass index, kg/m2, mean (minemax) 26.7 (18.8e38.4) 3 (0.1)
High density lipoprotein, mmol/L, mean (minemax) 1.2 (0.6e2.4) 40 (1.0)
Diabetes mellitus, N (%) 951 (21.9) 61 (1.4)
Number of affected sites due to vascular disease,a N (%) 0
1 3467 (78.7)
2 653 (14.8)
3 226 (5.1)
4 56 (1.3)
5 5 (0.1)
Creatinine, mmol/L, mean (minemax) 97.8 (54e825) 28 (0.6)
Albuminuria,b N (%) 256 (5.8)
No 3299 (79.5)
Micro 727 (17.5)
Macro 125 (3.0)
Intima media thickness, mm, mean (minemax) 0.93 (0.50e1.98) 104 (2.4)
Carotid artery stenosis,c N (%) 754 (17.5) 100 (2.3)
Composite end point
Cardiovascular death or myocardial infarction or stroke, N (%) 535 (12.1) 0
Individual component outcomes
Cardiovascular death, N (%) 324 (7.4) 0
Myocardial infarction, N (%) 310 (7.0) 0
Stroke, N (%) 136 (3.1) 0
Abbreviation: SMART, Second Manifestations of ARTerial disease.
a Sumscore of affected organs (cerebrum, cor, aorta, peripheral arteries). Aorta counts double.
b Microalbuminuria of 300 mg albumin secretion per 24 hours. Macroalbuminuria of O300 mg albumin secretion per 24 hours.
c Carotid artery stenosis greater than 50% confirmed by duplex.
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composite end point.
Table 3 shows the performance of the prediction model
when unadjusted absolute risks for the composite end point
were attributed to individual component outcomes. The
concordance index for the composite end point was 0.70
(95% confidence interval [CI]: 0.67, 0.73). The concor-
dance index for stroke and myocardial infarction was re-
spectively 0.70 (95% CI: 0.65, 0.74) and 0.68 (95% CI:
0.64, 0.71). The concordance index for cardiovascular
death was 0.79 (95% CI: 0.77, 0.82). The calibration plots
of respectively 3- and 5-year follow-up for the composite
end point were close to the dotted line where the predicted
risks equal the observed incidences indicating good calibra-
tion. However, for the individual component outcomes, the
line clearly deviated from the dotted line, indicating poor
calibration. Table 3 also presents the calibration of the pre-
diction model when the absolute risks for the individual
component outcomes were adjusted using our adaptation
method. Examples of how absolute risks are calculated
for the composite end point and one of the individual com-
ponents are presented in Appendix B on the journal’s Web
site at www.jclinepi.com. All the calibration plots showed
an improved level of calibration as all the calibration plots
shifted back toward the diagonal. Fig. 1 shows a score chart
(nomogram), by which absolute risks for the composite end
point (at 3 and 5 years) as well as the individual compo-
nents can easily be calculated. Although score charts arenot common in methodological studies, it clearly demon-
strates how prediction models with composite end points
can be presented.4. Discussion
In this article, we illustrated the limitation encountered
when absolute risks for composite end points are directly
attributed to individual component outcomes and suggested
an adaptation approach that can be used to mitigate them. An
example composite end point prediction model incorporat-
ing the component end points cardiovascular death, myocar-
dial infarction, and stroke was used as an example to
demonstrate the performance achieved when absolute risks
for 3- and 5-year survival from the composite end point were
directly interpreted for the individual component outcomes
without adjustment. The discriminative ability for all indi-
vidual component outcomes was good. For the important
cardiovascular death outcome, it performed significantly
better than the original composite model (concordance in-
dex, 0.79; 95% CI: 0.77, 0.82). Yet, unadjusted calibration
plots illustrate that the predicted risks from a composite
end point model cannot simply directly be attributed to their
individual component outcomes. As the incidence of the in-
dividual component outcomes was lower than that of the
composite end point, the unadjusted predicted risks were
by definition too high for the individual component
Table 3. Discrimination and calibration of the prediction model before and after adjustment of the absolute risks
Evaluated end points (N ) Concordance index (95% CI)
Calibration plots, 3 yra Calibration plots, 3 yra Calibration plots, 5 yrb Calibration plots, 5 yrb
Unadjusted Adjusted Unadjusted Adjusted
Composite end point (535) 0.70 (0.68, 0.73)
Cardiovascular death (324) 0.79 (0.77, 0.82)
Myocardial infarction (310) 0.68 (0.64, 0.71)
Stroke (136) 0.70 (0.65, 0.74)
Abbreviation: CI, confidence interval.
a Ranges of x-axis (predictions) and y-axis (Kaplan Meier estimates) from 0.7 to 1.
b Ranges of x-axis (predictions) and y-axis (Kaplan Meier estimates) from 0.5 to 1.
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Fig. 1. Nomogram to calculate 3- and 5-year survival probabilities of being free of a recurrent cardiovascular event. In the upper part, you can read
the points that you receive for every predictor separately. In the lower part, you can read the predicted survival for a particular end point after adding
up the points. Predictors: diabetes 15 present; stenosis 15 present; albumin 25microalbuminuria; albumin 35macroalbuminuria; affected
vascular site 1e55 sumscore of organs, previously affected by atherosclerotic disease (cerebrum, cor, aorta, peripheral arteries). An affected aorta
counts double. Example: A 75-year-old patient (5 points), BMI of 30 (2 points), HDL of 2 (2 points), no diabetes (0 points), previous aortic
aneurysm and peripheral arterial disease (4.5 points), a creatinine value of 100 (2.5 points), low albumin (0 points), no carotid stenosis (0 points),
and an IMT of 1 mm (2 points) presents to his physician. This makes a total of 18 points. The physician reads of from the nomogram that the
patient’s 5-year risk for cardiovascular disease is approximately 20% (1e0.8). The patient wants to know his risk for a stroke, which can be read
of as well: 6% (1e0.94). BMI, body mass index; HDL, high-density lipoprotein; IMT, Intima media thickness.
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must always be kept in mind when interpreting absolute risks
for composite end points. However, a simple adjustment to
the baseline hazard allows predicted risks to be estimated
for the individual component outcomes.
Obviously, individual component outcomes could also be
predicted with newly derived prediction models. The base-
line hazard and regression coefficients are then estimated
for the specific individual component outcome. However,
because of power reasons, it is often not feasible to derive
prediction models for individual component outcomes
[17,18]. Additionally, from a clinical point of view, it is im-
practical to have different prediction models for each indi-
vidual component outcomes. For general risk stratification
purposes, physicians may be more interested in composite
end points. However, in certain cases (when treatment
among individual outcomes differ, when patients should be
informed), individual risks might be useful. The purpose
of our adaptation method is to expand the usefulness of pre-
diction models with composite end points so that risks for in-
dividual component outcomes can be calculated as well
using the same prediction model.
For clinical trials, the disadvantages were previously de-
scribed: past publications have stated that the interpretation
of composite end points in trials could be complicated be-
cause of quantitative and qualitative heterogeneity of the de-
fined individual component outcomes [8,9,19]. This means
that individual components differ not only in their contribu-
tion to the composite end point but also in importance, for in-
stance in terms of impact on health, to patients. Others have
stressed that reporting of the distributions of the individual
components in composite end points is generally inadequate,
suggesting that the results apply to the individual component
outcomes rather than only to the overall composite end point.
Furthermore, it was stressed that results of studies with com-
posite end points lack relevance to patients [11,17,20]. These
disadvantages also pertain to composite end points used in
prognostic research. However, a lot can be avoided using
the adaptation method to adjust for the difference in inci-
dence between the composite end point and the individual
component outcomes.
Fortunately, the importance of this issue is becoming
more widely recognized. D’agostino et al. [5] also presented
a method to adjust the absolute risks of the FraminghamRisk
Score for its individual component outcomes. As to the best
of our knowledge, our adaptation method differs on two key
points. Composite end points are mainly calculated using
only one event per patient (usually the first event experi-
enced); conceivably other component end points are ignored.
A substantial amount of individual component outcomes
may be missed when only those events included in the com-
posite end point are used to calculate the calibration factor,
resulting in an underestimation of risks for individual com-
ponent outcomes. Considering the latter, we proposed to cal-
culate the calibration factor using the true incidence of an
individual component outcome rather than just theproportion included in the composite end point. Secondly,
by adjusting the baseline hazard instead of the absolute risk,
the current adaptation model accounts for the fact that Cox
regression follows an exponential function, whereby the ab-
solute risks are calculated with the relevant baseline hazard
and the fitted risk score. The baseline hazard is mainly deter-
mined by the incidence of the end point of interest. As we
correct for the difference in incidence in this study, we think
that it is mathematically more in keeping with the underlying
Cox function to adapt the baseline hazard rather than the re-
sultant absolute risks is mathematically.
Other methodological issues need to be addressed as well.
The adaptation method presumes an equal censoring pattern
for every end point involved. This assumption seems plausi-
ble, as the mean follow-up of the end points used in this
study did not differ excessively. The mean follow-up for
the composite end point was 1,485 days, whereas this was
1,554, 1,513, and 1,526 days for cardiovascular death, myo-
cardial infarction, and stroke, respectively. In any case, the
adaptation method also requiresdwhether it is used in the
same or in an external data setdthe incidence of the compo-
nent outcome and the baseline hazard for the composite end
point to be known. Unfortunately, this information is fre-
quently lacking from publications. The adaptation method
of D’agostino et al. [5] (see above) is a serviceable alterna-
tive in such cases. Note that the risks for the individual com-
ponent outcomes may then be underestimated. Furthermore,
repeating the procedure of this study could provide insight
into the stability of the approach. However, we did not intend
this article as an exhaustive methodological treatise on the
adaptation approach. We intended to bring up the point that
interpreting absolute risks is not as straightforward. Addi-
tionally, the adaptation method was introduced as a novel
concept to improve the interpretability in certain cases.
Lastly, we showed that a simple adjustment improved cali-
bration for the prediction of individual component out-
comes. As in clinical practice patients will increasingly be
treated based on their individual absolute risk, calibration
is a very important performance measure [21,22]. To en-
hance discrimination, a more rigorous adjustment is needed,
notably adding new predictors to the model [23,24]. Yet, as
far as we know, this has not been previously described for the
prediction of individual component outcomes from a predic-
tion model for composite end points.5. Conclusion
The most frequently addressed problem of composite end
points is interpretability for the individual component out-
comes [9e11,17,20]. We showed that the performance of
a prediction model indeed differs for the individual compo-
nent outcomes but that accurate predictions for component
outcomes can be made with a simple adjustment of the base-
line hazard in cases where the true incidence of said out-
comes are reported. Future developers of prediction
models can easily increase the utility of their composite
953M.J.A. Gondrie et al. / Journal of Clinical Epidemiology 65 (2012) 946e953end point prediction models by routinely reporting the base-
line hazard and the incidence of the individual component
outcomes. This gives readers an improved understanding
of the makeup of the composite end point and allows them
the opportunity to easily and accurately derive absolute risks
for the individual component outcomes. The clinical rele-
vance and utility of prediction future models may also read-
ily be increased by routinely reporting model’s performance
for the individual component outcomes. If the estimated in-
dividual risks perform well, the adaptation method can
safely be applied. Alternatively, if not new or updated pre-
dictive model needs to be constructed. Usability can be in-
creased by the inclusion of score charts (nomograms,
online risk calculators, etc.) for both the composite end point
as well as the individual component outcomes. Such perfor-
mance measures give an indication of whether adapted abso-
lute risks for the individual component outcomes are
accurate and well-constructed score charts simplify the cal-
culation of absolute risks. The presented adaptation method,
along with recommendations regarding the reporting of re-
sults, can increase the impact, interpretability, and utility
of both future and existing composite end point models.Supplementary material
Supplementary data associated with this article can
be found, in the online version, at 10.1016/j.jclinepi.2012.
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